Steller Launches Connected Content Solution for DMOs
Steller Connect allows destinations to integrate Trips by Steller™ itineraries and video into their website. The detailed itineraries are infused with influencer or traveler UGC video of each stop. Each stop includes vital travel information and is geotagged to an interactive map available on both web and mobile app. The viewer can switch between 3 views, list, map, and video allowing them to fully explore the destination.
The most valuable Steller Connect feature for DMOs is the connection to trip planning tools and marketing automation that truly makes a difference in getting people to their destination. The multi-channel journey retargets users through email and push notification to help them continue planning their own trip to the destination and booking it when it's time.
Transforming DMOs' Digital Strategy
Historically, DMOs have struggled to link influencer marketing efforts to measurable results. With Steller Connect, destinations can now:
Extend the lifespan of influencer content, keeping high performing content in front of prospective travelers for a year.
Connect short form video content and influencer recommendations to trip planning tools and retargeting automation.
Prove marketing ROI by tracking itinerary engagement, planned trips, and completed bookings.
'Measuring the true impact of travel influencer marketing has always been a challenge. Impressions and likes don't translate directly into booked hotel nights, and with the rising cost of influencer content, destinations are paying more for less visibility. Steller Connect keeps high-performing content in front of travelers for a full year and connects it to a booking journey. With built-in planning tools and detailed reporting, DMOs can finally see the real ROI of their influencer marketing efforts.' – Pete Bryant, CEO of Steller.
Early Adoption and Proven Success
Six destinations, including three international and three domestic, participated in the Steller Connect beta and saw impressive results.
Discover Puerto Rico implemented the tool in late October, embedding high performing influencer content and Trips by Steller™ itineraries into eight pages of their website. Seventy trips were planned through Steller Connect, with travel occurring within the first 90 days after the campaign concluded.
'We are extremely pleased with the results delivered by both campaigns we executed in partnership with Steller. A key component of these campaigns was Steller Connect, which Discover Puerto Rico integrated across eight landing pages on our website, including the homepage. We first added Video, followed a month later by Trips by Steller itineraries. This feature allows travelers to explore influencer-generated content, create personalized itineraries, and seamlessly book stays and experiences—driving economic impact for our destination. Pages featuring Steller Connect saw increases in Average Session Duration, indicating better engagement after its addition. With interactive maps, descriptions, and traveler reviews, it truly makes influencer marketing actionable and bookable' said Astrid Emmanuelli, Senior Social Media Manager of Discover Puerto Rico.
A Fully Connected Travel Planning Experience
The human experience is the most important part of the travel planning journey. People want to see themselves reflected in your content to feel comfortable enough to book a trip. With Steller Connect, DMOs can connect powerful stories from relatable influencers to an actionable, engaging, and measurable trip-planning experience. Visit Stellerforbusiness.com to learn more.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Wire
2 hours ago
- Business Wire
Invisalign® Palatal Expander System by Align Technology Now Available in Malaysia for Skeletal and Dental Expansion in Growing Patients
KUALA LUMPUR, Malaysia--(BUSINESS WIRE)--Align Technology, Inc. ('Align') (Nasdaq: ALGN) a leading global medical device company that designs, manufactures, and sells the Invisalign® System of clear aligners, iTero™ intraoral scanners, and exocad™ CAD/CAM software for digital orthodontics and restorative dentistry, today announced that Align's Invisalign Palatal Expander System* has been notified as Class B medical device by Malaysia Medical Device Authority and is now commercially available in Malaysia for broad patient applicability, including growing children, teens and adults (with surgery or other techniques). The Invisalign Palatal Expander System* is a modern and innovative direct 3D printed device based on proprietary and patented technology. Invisalign Palatal Expanders are intended for use in rapid expansion and subsequent holding of skeletal and/or dental narrow maxilla (upper jaw) with primary, mixed, or permanent dentition during treatment of patients. 'The Invisalign Palatal Expander System* exemplifies our commitment to advancing digital orthodontics with innovative solutions that enhance patient treatment experiences,' said David Carr, Align Technology executive vice president and managing director, Asia Pacific. 'We are excited to extend the availability of the transformative Invisalign Palatal Expander system, Align's first direct 3D printed orthodontic appliance, to even more doctors and their patients markets across the Asia Pacific region.' The Invisalign Palatal Expander System* consists of a series of removable devices staged in small increments of movement to expand a patient's narrow maxilla to a position determined by their treating doctor. Each direct 3D printed device is customized to the patient's unique anatomy based on an iTero™ intraoral digital scan. A palatal expansion treatment plan and device design are then developed using Align's proprietary AI-driven orthodontic software. Combined with Invisalign First™ aligners, Invisalign Palatal Expanders provide doctors with a full early intervention treatment solution for Phase 1 treatment, an early interceptive orthodontic treatment for young patients. Phase 1 treatment is traditionally done through arch expanders or partial metal braces, before all permanent teeth have erupted – typically at ages 6 through 10. Invisalign First clear aligners are designed specifically to address a broad range of younger patients' malocclusions, including shorter clinical crowns, management of erupting dentition, and predictable dental arch expansion. 'Phase 1 or early interceptive treatment accounts for 20 percent of orthodontic case starts each year and is growing,' said Dr. Mitra Derakhshan, Align Technology executive vice president, chief clinical officer, global treatment planning and clinical services. 'Together with Invisalign First aligners, Invisalign Palatal Expanders provide doctors with a solution set to treat the most common skeletal and dental malocclusions in growing children. The addition of mandibular advancement features to Invisalign aligners also provides doctors with more options for treating skeletal and dental jaw imbalances and bite correction for their growing patients during their teenage years.' The Invisalign Palatal Expander System* is available in Australia, New Zealand, Hong Kong, Singapore, Vietnam, Japan, Thailand, India and Malaysia. * Children shall not use device without supervision. About Align Technology, Inc. Align Technology designs and manufactures the Invisalign® System, iTero™ intraoral scanners and services, and exocad™ CAD/CAM software. These technology building blocks enable enhanced digital orthodontic and restorative workflows to improve patient outcomes and practice efficiencies for over 281.4 thousand doctor customers and is key to accessing Align's 600 million consumer market opportunity worldwide. Over the past 28 years, Align has helped doctors treat approximately 20.1 million patients with the Invisalign System and is driving the evolution in digital dentistry through the Align Digital Platform™, our integrated suite of unique, proprietary technologies and services delivered as a seamless, end-to-end solution for patients and consumers, orthodontists and GP dentists, and lab/partners. Visit for more information. For additional information about the Invisalign System or to find an Invisalign doctor in your area, please visit For additional information about the iTero digital scanning system, please visit For additional information about exocad dental CAD/CAM offerings and a list of exocad reseller partners, please visit Invisalign, iTero, exocad, Align, and Align Digital Platform are trademarks of Align Technology, Inc. About the Invisalign Palatal Expander System The Invisalign Palatal Expander System is a modern, innovative direct 3D printed orthodontic appliance designed based on proprietary and patented technology. The Invisalign Palatal Expander System is intended for the orthodontic treatment of malocclusion. The system is used for the rapid expansion and subsequent holding of skeletal and/or dental narrow maxilla (upper jaw, dental arch and teeth, palate) with primary, mixed, or permanent dentition during orthopedic treatment in children or adolescents. In adults, it is to be used in conjunction with surgery or other interventions when necessary. Devices are 3D printed and are manufactured based on digital scan data from commercially available iTero™ intraoral scanners offered by Align Technology, Ltd. The devices are removable for proper oral hygiene; manufactured to custom fit each patient's anatomy for optimal comfort and aesthetics, expanders fit comfortably in the patient's mouth and are changed daily (no screw required). The System is comprised of Invisalign Palatal Expanders (active expansion, each stage comes with a programmed expansion of up to 0.25mm/stage, changed daily or as per doctor's discretion) and Invisalign Palatal Holders (copies of the last stage of the expansion phase designed to hold the maxilla post-active expansion and changed every 2-4 weeks as directed by the treating doctor), Invisalign Attachment Templates and proprietary 3D shape generation software. These products are not available for purchase by the general public. However, the products are available for purchase from Invisalign® trained dentists and orthodontists.
Business Wire
3 hours ago
- Business Wire
REX-Osprey SOL + Staking ETF (SSK) Surpasses $100 Million AUM in Just 12 Trading Days
MIAMI--(BUSINESS WIRE)--REX-Osprey™ is proud to announce that the REX-Osprey™ SOL + Staking ETF (Ticker: SSK) has officially surpassed $100 million in assets under management — just 12 trading days after its launch on July 2, 2025.* *as of July 18th, 2025 SSK is the first U.S.-listed ETF to combine spot Solana (SOL) exposure with on-chain staking rewards, delivering a seamless way to participate in both SOL price appreciation and network-level income — all through a single ticker. 'Crossing the $100 million mark in just over two weeks underscores the appetite for innovative, blockchain-native solutions,' said Greg King, Founder & CEO of REX. 'With SSK, we're opening the door for mainstream investors to access the power of Solana staking through the familiar ETF wrapper.' SSK's strategy involves holding the majority of its assets in SOL and actively staking those assets on-chain. Investors benefit from: Direct price exposure to spot Solana On-chain staking rewards U.S.-listed, daily-liquid ETF structure No wallets or self-custody needed This milestone highlights the success of REX Shares' mission to bring modern crypto infrastructure into the ETF world — responsibly, transparently, and with investor access at the core. For standardized performance and more information, visit: Investing in SSK is not equivalent to investing directly in Solana. Investing in the Fund involves a high degree of risk. As with any investment, there is a risk that you could lose all or a portion of your investment in the Fund. An investor should carefully consider the Fund's investment objective, risks, charges, and expenses before investing. The Fund's prospectus and summary prospectus contain this and other information about the REX Shares. To obtain the Fund's prospectus and summary prospectus, call 1-844-802-4004. The Fund's prospectus and summary prospectus should be read carefully before investing. THE FUND, TRUST, ADVISER, AND SUB-ADVISER ARE NOT AFFILIATED WITH SOLANA OR ANY ENTITY PROVIDING VALIDATION OR STAKING SERVICES. The Fund's investment exposure is concentrated in the Solana ecosystem. Risks associated with this exposure may adversely affect the Fund's net asset value ('NAV') per share, trading price, yield, total return, and/or ability to meet its investment objective. The value of the Fund, which focuses on underlying securities in the crypto sector, may be more volatile than a more diversified pooled investment or the market as a whole and may perform differently from the value of a more diversified pooled investment or the market as a whole. Crypto Asset Risk. The Fund holds SOL tokens, a crypto asset that is native to the Solana blockchain. Crypto assets are subject to extreme volatility, regulatory uncertainty, market manipulation, security risks, and technological changes. The value of the Fund will fluctuate with the price of SOL, which is influenced by a range of factors including adoption of the Solana network, network congestion, smart contract failures, validator misbehavior, and the emergence of competing platforms. Additionally, crypto asset exchanges and counterparties may be less regulated than traditional financial institutions, and are subject to fraud, hacking, and operational disruptions. SOL Risk. The Fund's investments in SOL and SOL futures contracts expose the Fund to the risks associated with an investment in SOL because the price of these derivatives is substantially based on the price of SOL. SOL is a relatively new innovation and is subject to unique and substantial risks. The market for SOL is subject to rapid price swings, changes and uncertainty. Staking Risk. When the Fund stakes the Reference Asset, the Reference Asset is subject to the risks attendant to staking generally. Staking requires that the Fund lock up the staked Reference Asset for the period of time required by the staking protocol, meaning that the Fund cannot sell or transfer the staked Reference Asset, thereby making it illiquid for the period it is being staked. In addition, during the lock-up period, the Fund is subject to the market price volatility of the Reference Asset, and it may miss opportunities to sell the staked Reference Asset during opportune times. During the unstaking period, the Fund may miss out on earning opportunities because, in some cases, the staked Reference Asset may not earn rewards during the unstaking period or may only earn rewards during part of the unstaking period. Staked Reference Assets are also subject to security breaches, network downtime or attacks, smart contract vulnerabilities, and validator or custodian failure or compromise, which can result in a complete loss of the staked Reference Asset or a loss of any rewards. Concentration Risk. The Fund's assets will be concentrated in the sector or sectors or industry or group of industries that are assigned to the Reference Asset, which will subject the Fund to the risk that economic, political or other conditions that have a negative effect on those sectors and/or industries may negatively impact the Fund to a greater extent than if the Fund's assets were invested in a wider variety of sectors or industries. Liquidity Risk. The Fund may not be able to sell its crypto assets at the time or price it desires. Crypto asset markets may be less liquid than traditional securities markets and may be subject to significant price fluctuations. New Fund Risk. The Fund is a newly organized investment company with no operating history. Investors have limited performance history to assess how the Fund will perform. Non-Diversification Risk. The Fund is non-diversified, which means it may invest a greater percentage of its assets in a smaller number of issuers than a diversified fund. This may increase the volatility of the Fund's NAV and may lead to greater losses during periods of market declines. Indirect Investment Risk. Neither the Reference Asset nor the Ethereum Network nor the Solana Network are affiliated with the Trust, the Fund, or the Adviser, or any affiliates thereof and are not involved with this offering in any way, and have no obligation to consider the Fund in taking any actions that might affect the value of the Fund. None of the Trust, the Fund, the Adviser, or any affiliate are responsible for the performance of the Reference Asset and make no representation as to the performance of the Reference Asset. Investing in the Fund is not equivalent to investing in the Reference Asset. The Fund's performance is not intended to, nor will it, track the performance of the Reference Asset. Regulatory Risk. The Fund's investments in crypto assets may be subject to varying laws and regulations across jurisdictions, including tax laws and regulations. These laws and regulations may change without warning, and enforcement actions may be taken, which could have an adverse effect on the Fund and its operations. Custody Risk. The Reference Asset and other assets held by the Fund that operate on distributed ledger/blockchain technology can only be transferred by the person holding both the public and private keys to the digital wallet in which the asset is held. The Fund's custodians that custody the Fund's digital assets are on control of the private keys for each of the Fund's digital wallets. In the event such custodian loses sole control of the private keys (e.g., through a data breach or hack), the Fund's digital assets held by such custodian could be lost. Digital Assets Risk. The performance of the Reference Asset, and consequently the Fund's performance, is subject to the risks of the digital assets industry. The trading prices of many digital assets, including the Reference Asset, have experienced extreme volatility in recent periods and may continue to do so. Extreme volatility in the future, including further declines in the trading prices of the Reference Asset, could have a material adverse effect on the value of the Shares (defined below) and the Shares could lose all or substantially all of their value. The value of the Shares is subject to a number of factors relating to the fundamental investment characteristics of the Reference Asset as a digital asset, including the fact that digital assets are bearer instruments and loss, theft, destruction, or compromise of the associated private keys could result in permanent loss of the asset, and the capabilities and development of blockchain technologies. Digital assets represent a new and rapidly evolving industry, and the value of the Shares depends on the acceptance of the Reference Asset. Changes in the governance of a digital asset network may not receive sufficient support from users and miners, which may negatively affect that digital asset network's ability to grow and respond to challenges. Derivatives Risk. Derivatives are financial instruments, such as futures contracts, that derive value from the underlying reference asset or assets, such as stocks, bonds, or funds (including ETFs), interest rates or indexes. Foreign Securities Risk. To the extent the Fund invests in foreign securities, they may be subject to additional risks not typically associated with investments in domestic securities. Counterparty Risk. The Fund may rely on staking infrastructure providers, custodians, and crypto exchanges to hold or interact with its SOL. These third parties may become insolvent, fail to safeguard assets, or be subject to regulatory action, leading to potential losses. Smart Contract Risk. Certain staking activities or custodial processes may rely on smart contracts. These self-executing code structures are susceptible to bugs, hacking, or unintended behavior. Exploits in smart contracts could cause loss of assets or incorrect reward distribution. Market Risk. The value of the Fund's investments may decline due to market movements, economic conditions, or other factors affecting the overall crypto asset market or Solana ecosystem. Distributor: Foreside Fund Services, LLC, member FINRA, not affiliated with REX Shares, Osprey Funds, or the Fund's investment adviser.
Hamilton Spectator
5 hours ago
- Hamilton Spectator
Eupraxia Pharmaceuticals Invited to Present at Upcoming Investor Conferences
VICTORIA, British Columbia, July 22, 2025 (GLOBE NEWSWIRE) — Eupraxia Pharmaceuticals Inc. ('Eupraxia' or the 'Company') (NASDAQ:EPRX) (TSX:EPRX), a clinical-stage biotechnology company leveraging its proprietary DiffuSphere™ technology designed to optimize local, controlled drug delivery for applications with significant unmet need, today announced that the Company's management team will present and participate at the following upcoming investor conferences: Canaccord Growth 45th Annual Growth Conference Date: August 12 - 14, 2025 Presentation date & time: August 13, 2025, 9:30am ET Location: Boston, MA Citi Biopharma Back to School Conference Date: September 2-3, 2025 Location: Boston, MA Cantor Global Healthcare Conference Date: September 3-5, 2025 Presentation date & time: September 5, 2025, 9:10am ET Location: New York, NY H.C. Wainwright 27th Annual Global Investment Conference Date: September 8-10, 2025 Location: New York, NY About Eupraxia Pharmaceuticals Inc. Eupraxia is a clinical-stage biotechnology company focused on the development of locally delivered, extended-release products that have the potential to address therapeutic areas with high unmet medical need. DiffuSphere™, a proprietary, polymer-based micro-sphere technology, is designed to facilitate targeted drug delivery of both existing and novel drugs. The technology is designed to support extended duration of effect and delivery of drugs in a hyper-localized fashion, targeting only the tissues that physicians are wanting to treat. We believe the potential for fewer adverse events may be achieved through the precision targeting and the stable and flat delivery of the active ingredient when using the DiffuSphere™ technology, versus the peaks and troughs seen with more traditional drug delivery methods. The precision of Eupraxia's DiffuSphere™ technology platform has the potential to augment and transform existing FDA-approved drugs to improve their safety, tolerability, efficacy and duration of effect. The potential uses in therapeutic areas may go beyond pain and inflammatory gastrointestinal disease, where Eupraxia currently is developing advanced treatments, to also be applicable in oncology, infectious disease and other critical disease areas. Eupraxia's EP-104GI is currently in a Phase 1b/2 trial, the RESOLVE trial, for the treatment of EoE. EP-104GI is administered as an injection into the esophageal wall, providing local delivery of drug. This is a unique treatment approach for EoE. Eupraxia also recently completed a Phase 2b clinical trial (SPRINGBOARD) of EP-104IAR for the treatment of pain due to knee osteoarthritis. The trial met its primary endpoint and three of the four secondary endpoints. In addition, Eupraxia is developing a pipeline of later and earlier-stage long-acting formulations. Potential pipeline indications include candidates for other inflammatory joint indications and oncology, each designed to improve on the activity and tolerability of currently approved drugs. For further details about Eupraxia, please visit the Company's website at: . Notice Regarding Forward-looking Statements and Information This news release includes forward-looking statements and forward-looking information within the meaning of applicable securities laws. Often, but not always, forward-looking information can be identified by the use of words such as 'plans', 'is expected', 'expects', 'suggests', 'scheduled', 'intends', 'contemplates', 'anticipates', 'believes', 'proposes', 'potential' or variations (including negative and grammatical variations) of such words and phrases, or state that certain actions, events or results 'may', 'could', 'would', 'might' or 'will' be taken, occur or be achieved. Forward-looking statements in this news release include statements regarding the expected enrollment and number of sites for the Phase 2b portion of the RESOLVE study; the expected parameters of the RESOLVE study; the availability of topline data and release of additional long-term data with higher doses and timing thereof; the Company's product candidates, including their expected benefits to patients with respect to safety, tolerability, efficacy and duration; the expectations around proceeding to clinical trials for the Company's product candidates; the results gathered from studies and trials of Eupraxia's product candidates; the potential for the Company's technology to impact the drug delivery process; potential market opportunity for the Company's product candidates; and potential pipeline indications. Such statements and information are based on the current expectations of Eupraxia's management, and are based on assumptions, including but not limited to: future research and development plans for the Company proceeding substantially as currently envisioned; industry growth trends, including with respect to projected and actual industry sales; the Company's ability to obtain positive results from the Company's research and development activities, including clinical trials; and the Company's ability to protect patents and proprietary rights. Although Eupraxia's management believes that the assumptions underlying these statements and information are reasonable, they may prove to be incorrect. The forward-looking events and circumstances discussed in this news release may not occur by certain dates or at all and could differ materially as a result of known and unknown risk factors and uncertainties affecting Eupraxia, including, but not limited to: risks and uncertainties related to the Company's limited operating history; the Company's novel technology with uncertain market acceptance; if the Company breaches any of the agreements under which it licenses rights to its product candidates or technology from third parties, the Company could lose license rights that are important to its business; the Company's current license agreement may not provide an adequate remedy for its breach by the licensor; the Company's technology may not be successful for its intended use; the Company's future technology will require regulatory approval, which is costly and the Company may not be able to obtain it; the Company may fail to obtain regulatory approvals or only obtain approvals for limited uses or indications; the Company's clinical trials may fail to demonstrate adequately the safety and efficacy of its product candidates at any stage of clinical development; the Company may be required to suspend or discontinue clinical trials due to side effects or other safety risks; the Company completely relies on third parties to provide supplies and inputs required for its product candidates and services; the potential impact of tariffs on the cost of the Company's active pharmaceutical ingredients and clinical supplies of EP-104IAR and EP-104GI; the Company relies on external contract research organizations to provide clinical and non-clinical research services; the Company may not be able to successfully execute its business strategy; the Company will require additional financing, which may not be available; any therapeutics the Company develops will be subject to extensive, lengthy and uncertain regulatory requirements, which could adversely affect the Company's ability to obtain regulatory approval in a timely manner, or at all; the impact of health pandemics or epidemics on the Company's operations; the Company's restatement of its consolidated financial statements, which may lead to additional risks and uncertainties, including loss of investor confidence and negative impacts on the Company's common share price; and other risks and uncertainties described in more detail in Eupraxia's public filings on SEDAR+ ( and EDGAR ( Although Eupraxia has attempted to identify important factors that could cause actual actions, events or results to differ materially from those described in forward-looking statements and information, there may be other factors that cause actions, events or results to differ from those anticipated, estimated or intended. No forward-looking statement or information can be guaranteed. Except as required by applicable securities laws, forward-looking statements and information speak only as of the date on which they are made and Eupraxia undertakes no obligation to publicly update or revise any forward-looking statement or information, whether as a result of new information, future events or otherwise. For investor and media inquiries, please contact: Danielle Egan, Eupraxia Pharmaceuticals Inc. 778.401.3302 degan@ or Kevin Gardner, on behalf of: Eupraxia Pharmaceuticals Inc. 617.283.2856 kgardner@ SOURCE Eupraxia Pharmaceuticals Inc.
